Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer—a study by the OVCAD consortium

Melmer, Andreas; Fineder, Linda; Lamina, Claudia; Kollerits, Barbara; Dieplinger, Benjamin; Braicu, Elena Ioana; Sehouli, Jalid; Cadron, Isabelle; Vergote, Ignace; Mahner, Sven; Zeimet, Alain G.; Castillo‐Tong, Dan Cacsire; Ebenbichler, Christoph; Zeillinger, Robert; Dieplinger, Hans

doi:10.1016/j.ygyno.2012.09.032

Cited by 23 publications

(14 citation statements)

References 35 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…median afamin plasma concentrations were 41 mg/dL in 215 patients with ovarian cancer [10] as compared to the rather low afamin concentrations we report for inflammatory disorders in the present study. Therefore, afamin plasma concentrations should be interpreted only in the context of comorbidities and inflammatory biomarker status.…”

Section: Discussioncontrasting

confidence: 66%

“…Patients with ovarian cancer displayed significantly decreased plasma concentrations of afamin by comparison to healthy controls. These results were later validated in an independent larger study of patients with ovarian cancer [9] and, very recently, extended by showing significant associations between afamin plasma concentrations and clinical outcomes (response to therapy and survival rates) [10]. In contrast, afamin concentrations were not found to be decreased in benign gynecological conditions including endometriosis [9,11].…”

Section: Introductionmentioning

confidence: 89%

See 1 more Smart Citation

Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma

Dieplinger

Egger

Gabriel

et al. 2013

Clinica Chimica Acta

Self Cite

View full text Add to dashboard Cite

BackgroundComparative proteomics has recently identified afamin, the newest member of the albumin gene family, as a potential biomarker for ovarian cancer. The aim of this study was the analytical and clinical evaluation of a sandwich enzyme-linked immunosorbent assay for the determination of afamin in human plasma.MethodsWe evaluated precision, linearity, and detection limit of the assay, analyte stability and biological variability, determined reference values and quantified afamin concentrations in various diseases.ResultsWithin-run and total coefficients of variation were < 10%. The method was linear across the tested measurement range. Detection limit was 7 mg/L for the assay. The analyte was stable for 24 h at room temperature, for 48 h at 4 °C, and for at least one year at − 20 °C and − 80 °C. The reference change value for healthy individuals was 24%. Age- and sex-independent reference values in healthy blood donors were 45–99 mg/L (median 68 mg/L). In the clinical assay evaluation afamin plasma concentrations were modestly decreased in patients with heart failure. Patients with pneumonia or sepsis exhibited markedly decreased afamin plasma concentrations. However, patients with chronic renal disease or chronic obstructive pulmonary disease showed no difference in afamin plasma concentrations as compared to healthy individuals. Correlation analyses revealed an inverse association between afamin and inflammatory biomarkers.ConclusionsThe afamin assay meets quality specifications for laboratory medicine. The results of the clinical assay evaluation revealed novel insights with respect to afamin as a potential negative acute phase protein and should encourage further studies.

show abstract

Section: Discussioncontrasting

confidence: 66%

Section: Introductionmentioning

confidence: 89%

Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma

Dieplinger

Egger

Gabriel

et al. 2013

Clinica Chimica Acta

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients with ovarian cancer displayed significantly decreased plasma concentrations of afamin by comparison to healthy controls. These results were later validated in an independent larger study of patients with ovarian cancer [17] and, very recently, extended by showing significant associations between afamin plasma concentrations and clinical outcomes (response to therapy and survival rates) [24]. In contrast, afamin concentrations were not found to be decreased in benign gynecological conditions including endometriosis [17,25].…”

Section: Clinical Applications Of Afamin Measurementmentioning

confidence: 80%

Afamin — A pleiotropic glycoprotein involved in various disease states

Dieplinger

2015

Clinica Chimica Acta

Self Cite

View full text Add to dashboard Cite

The human glycoprotein afamin was discovered as the fourth member of the albumin gene family. Despite intense research over the last 20 years, our knowledge of afamin's physiological or pathophysiological functions is still very limited. Circulating afamin is primarily of hepatic origin and abundant concentrations are found in plasma, cerebrospinal, ovarian follicular and seminal fluids. In vitro binding studies revealed specific binding properties for vitamin E. A previously performed analytical characterization and clinical evaluation study of an enzyme-linked immunosorbent assay for quantitative measurement of afamin in human plasma demonstrated that the afamin assay meets the quality specifications for laboratory medicine. Comparative proteomics has identified afamin as a potential biomarker for ovarian cancer and these findings were confirmed by quantitative immunoassay of afamin and validated in independent cohorts of patients with ovarian cancer. Afamin has also been investigated in other types of carcinoma. Most of these studies await further evaluation with validated quantitative afamin assays and require validation in larger patient cohorts. Transgenic mice overexpressing the human afamin gene revealed increased body weight and increased blood concentrations of lipids and glucose. These transgenic mouse data were in line with three large human population-based studies showing that afamin is strongly associated with the prevalence and development of the metabolic syndrome. This review summarizes and discusses the molecular, biochemical and analytical characterization of afamin as well as possible clinical applications of afamin measurement.

show abstract

“…Diseases including pregnancy complications (Hubalek et al, 2014), metabolic syndrome (diabetes mellitus, obesity and hypertension), polycystic ovary syndrome (Koninger et al, 2014) have been showed associated with AFM as well. In cancer field, afamin was identified as a potential biomarker for ovarian cancer (Dieplinger et al, 2009;Jackson et al, 2007) and its plasma concentration was related to response to therapy and survival rates (Melmer et al, 2013). In thyroid cancer, one of our previous studies demonstrated that significant differences between the protein expression profiles of PTC patients with 131 I-avid lung metastases and those with non-131 I-avid lung metastases were detected by proteomic analysis and afamin was downregulated in the serum of PTC patients with non-131 I-avid lung metastases (Song et al, 2013).…”

Section: Discussionmentioning

confidence: 99%